The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction
Value in Health · 2025
DOI: 10.1016/j.jval.2024.12.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2025. Verfasst von Sanne J J P M Metsemakers und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands. Electronic address: Sanne.Metsemakers@radboudumc.…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Radboud Universitair Medisch Centrum.
Abstract (Originalsprache)
OBJECTIVES: The management of chronic myeloid leukemia (CML) now includes dose reduction (DR) and treatment-free remission (TFR). Evaluating the cost-effectiveness of lifelong-prescribed expensive tyrosine kinase inhibitors (TKIs) for CML is crucial. Prior cost-effectiveness evaluations state that imatinib is the favorable frontline TKI. Some of these evaluations address TFR, but not DR, nor aging and second-generation (2G)-TKIs upcoming patent expirations. This study evaluates the cost-effectiveness of frontline TKIs for CML patients including these factors. METHODS: This Markov model evaluates the cost-effectiveness of frontline TKIs for newly diagnosed patients with CML using 17 health states. Transition probabilities, costs, and utilities were derived from literature data. Incremental cost-effectiveness ratios were calculated. Sensitivity analysis and model validation were conducted. RESULTS: Nilotinib is most effective (20.13 quality-adjusted life-years [QALYs]) and imatinib is least effective (17.25 QALYs) for the model including TFR and DR. Imatinib was favored over dasatinib (89.80%), nilotinib (62.70%), and bosutinib (78.40%), at a willingness-to-pay threshold of €80 000 per QALY. Without TFR and DR, fewer QALYs were generated. For patients at the age of 70 years, imatinib has a high probability of being more cost-effective than dasatinib, nilotinib, and bosutinib. With 50% 2GTKI cost reductions, nilotinib is considered more cost-effective compared with imatinib (98.40%), dasatinib (94.80%), and bosutinib (68.90%). CONCLUSIONS: The findings indicate that 2GTKIs are more effective in generating QALYs, including for older (age >70 years) patients. Given the current TKI prices, imatinib remains cost-effective. Including DR and TFR in CML management generates more QALYs. Cost reductions from expected 2GTKIs patent expirations will greatly increase their cost-effectiveness. Results may inform 2GTKIs cost discussions after patent expiration, potentially broadening global availability. The findings also emphasize the importance of aiming for TFR and DR in CML management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands. Electronic address: Sanne.Metsemakers@radboudumc.nl.
- Department of IQ Health, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands.
- Department of Hematology, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands.
- Medip Analytics, Nijmegen, Gelderland, The Netherlands; Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Gelderland, The Netherlands.
Förderung
- Radboud Universitair Medisch Centrum
Zitieren
APA
Metsemakers, S. J. J. P. M., Hermens, R. P. M. G., Ector, G. I. C. G., Blijlevens, N. M. A., & Govers, T. M. (2025). The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction. Value in Health. https://doi.org/10.1016/j.jval.2024.12.005
Vancouver
Metsemakers SJJPM, Hermens RPMG, Ector GICG, Blijlevens NMA, Govers TM. The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction. Value in Health. 2025. doi:10.1016/j.jval.2024.12.005
BibTeX
@article{Metsemakers2025,
author = {Metsemakers, Sanne J J P M and Hermens, Rosella P M G and Ector, Geneviève I C G and Blijlevens, Nicole M A and Govers, Tim M},
title = {The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction},
journal = {Value in Health},
year = {2025},
doi = {10.1016/j.jval.2024.12.005}
}
EUVIMED